11.04.2013 - Fuelled by €1.1m of EU money, six European partners from industry and academia plan to find kinase-targeting drugs in a venture called TAKTIC.
A focussed group of three SMEs and three academic partners form the Translational Kinase Tumour Inhibitor Discovery Consortium (TAKTIC). Members announced on 10 April the creation of the consortium which is financed to the tune of €1.1m by the EU’s 7th Framework Programme “Research for the Benefit of SMEs”. The industry partners comprise SARomics Biostructures from Lund (Sweden), Prestwick Chemical from Illkirch (France) and ProQinase GmbH from Freiburg (Germany). The collaborating academic scientists work at the University of Turin (Italy) the Israel Structural Proteomics Center (ISPC) at the Weizmann Institute of Science and the TechMedIll platform of the University of Strasbourg (France).
Targeting kinases has become one of the most important therapeutic opportunities for treating cancer, diabetes, inflammatory diseases and more. The TAKTIC Consortium offers its members extensive expertise in medicinal chemistry, kinase biochemistry as well as state-of-the-art high-throughput platforms for protein expression and crystallisation. The merging of the highly complementary capabilities of the six partners within TAKTIC enables an efficient and versatile kinase drug discovery platform that will target some challenging and medically important kinases, the partners said in a joint press release.
17.04.2014 The European Parliament has given green light to the second Innovative Medicines Initiative with the aim to advance pharmacological research and development, particularly in areas of unmet medical need.
11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.
09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.
08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.
The LiposoFast-Basic produces unilamellar liposomes by the manual extrusion of a multilamellar liposome suspension through a polycarbonate membrane of defined pore size, using gas-tight, glass syringes. more